Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

G1 Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2008-01-01

Employees: 100

Market Cap: $376.1M

Website: http://www.g1therapeutics.com

Clinical Trials

Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

Phase 4

Recruiting

Conditions: Extensive-stage Small-cell Lung Cancer

Interventions: Drug: Placebo
Drug: Trilaciclib
Drug: Topotecan

First Posted Date: 2023-05-24

Last Posted Date: 2023-11-07

Lead Sponsor: G1 Therapeutics, Inc.

Target Recruit Count: 302

Registration Number: NCT05874401

Locations: 🇦🇹
Klinikum Klagenfurt am Wörthersee, Klagenfurt am Worthersee, Austria
🇦🇹
Klinik Hietzing, Vienna, Austria
🇦🇹
Wiener Gesundheitsverband Klinik Penzing, Wien, Austria

and more 53 locations

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Phase 2

Terminated

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Trilaciclib
Drug: Sacituzumab Govitecan-hziy

First Posted Date: 2021-11-09

Last Posted Date: 2025-01-29

Lead Sponsor: G1 Therapeutics, Inc.

Target Recruit Count: 30

Registration Number: NCT05113966

Locations: 🇺🇸
Ironwood Physicians, Chandler, Arizona, United States
🇺🇸
Comprehensive Blood & Cancer Center, Bakersfield, California, United States
🇺🇸
Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States

and more 19 locations

Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Triple Negative Breast Cancer

Interventions: Drug: Trilaciclib
Drug: Cylophosphamide
Drug: Doxorubicin
Drug: Paclitaxel
Drug: Carboplatin (Investigator discretion)
Biological: Pembrolizumab (Investigator discretion)

First Posted Date: 2021-11-09

Last Posted Date: 2024-03-12

Lead Sponsor: G1 Therapeutics, Inc.

Target Recruit Count: 24

Registration Number: NCT05112536

Locations: 🇺🇸
Cancer and Blood Specialty Clinic, Los Alamitos, California, United States
🇺🇸
UCLA Department of Medicine - Hematology/Oncology, Santa Monica, California, United States
🇺🇸
PIH Health, Whittier, California, United States

and more 4 locations

Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab

Phase 2

Terminated

Conditions: Myelosuppression Adult
Bladder Cancer
Urothelial Carcinoma
Chemotherapy-induced Neutropenia
Metastatic Bladder Cancer

Interventions: Drug: Gemcitabine
Drug: Trilaciclib
Drug: Cisplatin
Drug: Carboplatin
Drug: Avelumab

First Posted Date: 2021-05-14

Last Posted Date: 2024-03-22

Lead Sponsor: G1 Therapeutics, Inc.

Target Recruit Count: 92

Registration Number: NCT04887831

Locations: 🇺🇸
Valkyrie Clinical Trial, Los Angeles, California, United States
🇺🇸
The Oncology Institute of Hope and Innovation, Whittier, California, United States
🇺🇸
Rocky Mountain Cancer Centers, Littleton, Colorado, United States

and more 31 locations

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)

Phase 2

Terminated

Conditions: NSCLC
Metastatic Non-Small Cell Lung Cancer
Lung Cancer

Interventions: Drug: Placebo
Drug: Trilaciclib
Drug: Docetaxel

First Posted Date: 2021-04-28

Last Posted Date: 2023-04-14

Lead Sponsor: G1 Therapeutics, Inc.

Target Recruit Count: 10

Registration Number: NCT04863248

Locations: 🇺🇸
Ironwood Cancer & Research Centers, Phoenix, Arizona, United States
🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸
Desert Hematology Oncology Medical Group, Inc, Rancho Mirage, California, United States

and more 9 locations

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

Phase 3

Completed

Conditions: TNBC - Triple-Negative Breast Cancer
Breast Cancer

Interventions: Drug: Placebo
Drug: Trilaciclib
Drug: Gemcitabine
Drug: Carboplatin

First Posted Date: 2021-03-16

Last Posted Date: 2024-08-01

Lead Sponsor: G1 Therapeutics, Inc.

Target Recruit Count: 194

Registration Number: NCT04799249

Locations: 🇺🇸
Banner M.D. Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
Washington Cancer Institute at MedStar Washington Hospital Center - Oncology Research, Washington, District of Columbia, United States
🇺🇸
Florida Cancer Specialists - North (SCRI), Saint Petersburg, Florida, United States

and more 68 locations

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):

Phase 3

Terminated

Conditions: Colorectal Cancer Metastatic
Myelosuppression-Adult
Chemotherapeutic Toxicity

Interventions: Drug: Trilaciclib
Drug: Placebo

First Posted Date: 2020-10-29

Last Posted Date: 2024-11-26

Lead Sponsor: G1 Therapeutics, Inc.

Target Recruit Count: 326

Registration Number: NCT04607668

Locations: 🇺🇸
AZ Oncology Associates - HOPE, Tucson, Arizona, United States
🇺🇸
Beverly Hills Cancer Center, Beverly Hills, California, United States
🇺🇸
Keck Medical Center of USC Pasadena, Los Angeles, California, United States

and more 79 locations

Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer

Conditions: Myelosuppression Adult
Chemotherapeutic Toxicity
Small Cell Lung Cancer

First Posted Date: 2020-08-07

Last Posted Date: 2021-03-19

Lead Sponsor: G1 Therapeutics, Inc.

Registration Number: NCT04504513

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung
Lung Cancer
Non-small Cell Lung Cancer

Interventions: Drug: G1T38
Drug: Osimertinib

First Posted Date: 2018-03-07

Last Posted Date: 2023-05-06

Lead Sponsor: G1 Therapeutics, Inc.

Target Recruit Count: 30

Registration Number: NCT03455829

Locations: 🇺🇸
Beverly Hills Cancer Center, Beverly Hills, California, United States
🇺🇸
UCLA Medical Center, Division of Hematology/Oncology/Clinical Research Unit, Santa Monica, California, United States
🇺🇸
St Joseph Heritage Healthcare, Santa Rosa, California, United States

and more 5 locations

G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer

Phase 1

Completed

Conditions: Carcinoma, Ductal, Breast
Metastatic Breast Cancer
Stage IV Breast Cancer
Breast Cancer Female
Breast Neoplasm
Breast Cancer
Advanced Breast Cancer

Interventions: Drug: G1T48
Drug: Palbociclib

First Posted Date: 2018-03-06

Last Posted Date: 2022-12-15

Lead Sponsor: G1 Therapeutics, Inc.

Target Recruit Count: 107

Registration Number: NCT03455270

Locations: 🇺🇸
Beverly Hills Cancer Center, Beverly Hills, California, United States
🇺🇸
Stanford Women Cancer Center, Stanford, California, United States
🇺🇸
Northwestern University - Feinberg School of Medicine, Chicago, Illinois, United States

and more 12 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy